Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| RH01910 | Other Identifier | GSK |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Carbon dioxide (CO2) is a naturally occurring gas that readily diffuses across body tissues and membranes. Data from earlier clinical studies conducted in 975 subjects with allergic rhinitis have shown that nasally administered CO2 may provide relief of the associated symptoms. Symptom relief has been shown to occur as soon as 10 minutes after administration, and may persist for four to six hours.
This study aims to assess the consumer appeal of a prototype CO2 delivery device, as well as evaluate its perceived effectiveness for nasal congestion. Properly consented subjects who qualify and choose to participate in the clinical study will be administered nasal CO2 under medical supervision, wait a period of 1 hour in clinic, and then be dispensed a device for self-treatment at home. Subjects will return to the clinic on day 7 for final evaluation and completion of assessment questionnaires.
This study will be conducted in two parts. In the first part of the study, recruited subjects with nasal congestion will view a description of a new treatment option (concept). Interested subjects will be offered the opportunity to enter the clinical trial. Subjects who consent and are found otherwise eligible will then receive one dose of CO2 in the study clinic under medical supervision. Afterward, subjects who wish to continue will be allowed to take the administration device home for an additional six days of use (study part 2).
During the at-home use portion of the study, subjects will use a diary to record the number of times the product was used and their nasal congestion symptoms before and after use.
At the end of the study period, subjects will return to the study center for global assessment of their impressions of treatment and to answer questions designed to estimate market acceptability. Subjects may be asked to participate voluntarily in a market research focus group following their participation in this study.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment Group | Experimental | Participants will receive one dose of nasal carbon dioxide (CO2) in the study clinic under medical supervision, followed by an additional six days of at home use, up to 4 times per day. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Carbon Dioxide | Drug | Nasal administration of carbon dioxide (CO2) through the delivery device for 10 seconds |
|
| Measure | Description | Time Frame |
|---|---|---|
| Which One Product That Relieves Nasal Congestion do You Buy Most Often? | There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked as part of screening survey prior to concept viewing. If the participant answered "I do not purchase any product to relieve congestion" the participant was excluded. Participants could select only one option available. | 7 days |
| Which of the Statements Best Describes the Extent to Which the Spray Reached Your Expectations? | There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after the first use. Participants could select only one option. | 7 days |
| If the Product You Just Tried (After First Dose) Was Available for the Following Price: $12.99 for 40 Doses, How Likely Would You be to Buy it? | There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after the first dose of the product. Participants could select only one option. | 7 days |
| Would You be Interested in Taking the Spray Product Home and Using it Over the Next Week? | There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after the first dose of the product. Participants could select only one option. | 7 days |
| Which of the Following Statements Best Describes the Extent to Which the Spray Reached Your Expectations? | There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after at-home use of the product. Participants could select only one option. |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| GSK Clinical Trials | GlaxoSmithKline | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Radiant Research - Chandler, AZ | Chandler | Arizona | 85224 | United States | ||
| Radiant Research - Pinellas Park, FL |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 27178892 | Derived | Johnson SM, Hamilton AM, Lauersen LA. A phase IV, single-center, crossover evaluation of the efficacy of an external nasal dilator strip in children with nasal congestion. Allergy Asthma Proc. 2016 May;37(3):242-7. doi: 10.2500/aap.2016.37.3950. |
Not provided
Not provided
This was a 2-part study. In Part 1, recruited participants viewed a description of new treatment option (concept). Interested participants entered the trial. Eligible participants who consented received one dose of nasal CO2 in the clinic under medical supervision. Participants who wished to continue took the device home for 6 days (Part 2).
Adult subjects with nasal congestion were recruited at the study sites from their volunteer database and through advertising.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | CO2 Nasal Spray | CO2 spray was administered for 10 seconds per nostril. Participants received one dose of nasal CO2 in the study clinic under medical supervision, followed by an additional six days of at home use, up to 4 times per day |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | CO2 Nasal Spray | CO2 spray was administered for 10 seconds per nostril. Participants received one dose of nasal CO2 in the study clinic under medical supervision, followed by an additional six days of at home use, up to 4 times per day |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Which One Product That Relieves Nasal Congestion do You Buy Most Often? | There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked as part of screening survey prior to concept viewing. If the participant answered "I do not purchase any product to relieve congestion" the participant was excluded. Participants could select only one option available. | The per protocol (PP) population was the primary population for analysis. Of the 143 participants who completed this study, 10 participants had device failure (device that didnot perform well), and therefore 133 participants were included in PP population. | Posted | Number | Participants | 7 days |
|
Adverse events were collected from the start of the investigational product, and until 3 days following last administration of the investigational product.
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | CO2 Nasal Spray | CO2 spray was administered for 10 seconds per nostril. Participants received one dose of nasal CO2 in the study clinic under medical supervision, followed by an additional six days of at home use, up to 4 times per day |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Nasal discomfort | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| GSK Response Center | GlaxoSmithKline | 866-435-7343 |
Not provided
| ID | Term |
|---|---|
| D015508 | Nasal Obstruction |
| ID | Term |
|---|---|
| D009668 | Nose Diseases |
| D012140 | Respiratory Tract Diseases |
| D000402 | Airway Obstruction |
| D012131 | Respiratory Insufficiency |
Not provided
Not provided
| ID | Term |
|---|---|
| D002245 | Carbon Dioxide |
| ID | Term |
|---|---|
| D017554 | Carbon Compounds, Inorganic |
| D007287 | Inorganic Chemicals |
| D005740 | Gases |
| D010087 | Oxides |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 7 days |
| Divide 11 Points Between Two Products (CO2 Nasal Spray and Brand Selected at Q1)? | There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after at-home use of the product. Participants could select only one option. It was done to compare the spray with the product selected by the participant in Q1. There were 11 points between the two products that participants could divide anyways thet wanted (11-0, 10-1, 9-2, 8-3, 7-4 or 6-5 etc). The more the participant liked a product compared to other, the higher the number of points were to be given to that product. | 7 days |
| If the Product You Just Tried (After At-home Use) Was Available for the Following Price: $12.99 for 40 Doses, How Likely Would You be to Buy it? | There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after at-home use of the product. Participants could select only one option. | 7 days |
| How Many Packages Would You Buy? | There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience.This question was asked after at-home use of the product. Participants could select only one option. | 7 days |
| Which One Statement Best Describes How Often, if Ever, You Think You Would Buy the Spray Product in the Future? | There was one questionnaire used in this study which is divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after at-home use of the product. Participants could select only one option. | 7 days |
| How Often do You Think This Spray Product Would Last for You Personally? | There was one questionnaire used in this study which is divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after at-home use of the product. Participants could select only one option. | 7 days |
| Provide a Score From 1-7 to Some Statements, Depending on How Much You Think Each Statement Applies or Does Not Apply to the Spray Product That You Used | A score of 1 indicates that the statement does not apply at all to the product that you used. A score of 7 indicates that it applies completely to it. You can use any score from 1 to 7 to indicate how much or how little you think the statement applies to this product | 7 days |
| Pinellas Park |
| Florida |
| United States |
| TKL Research Inc | Paramus | New Jersey | 07652 | United States |
| Radiant Research - Cincinnati | Cincinnati | Ohio | 45249 | United States |
| Years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
|
|
| Primary | Which of the Statements Best Describes the Extent to Which the Spray Reached Your Expectations? | There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after the first use. Participants could select only one option. | The per protocol (PP) population was the primary population for analysis. Of the 143 participants who completed this study, 10 participants had device failure (device that did not perform well), and therefore 133 participants were included in PP population. | Posted | Number | Participants | 7 days |
|
|
|
| Primary | If the Product You Just Tried (After First Dose) Was Available for the Following Price: $12.99 for 40 Doses, How Likely Would You be to Buy it? | There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after the first dose of the product. Participants could select only one option. | The per protocol (PP) population was the primary population for analysis. Of the 143 participants who completed this study, 10 participants had device failure (device that did not perform well), and therefore 133 participants were included in PP population. | Posted | Number | Participants | 7 days |
|
|
|
| Primary | Would You be Interested in Taking the Spray Product Home and Using it Over the Next Week? | There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after the first dose of the product. Participants could select only one option. | The per protocol (PP) population was the primary population for analysis. Of the 143 participants who completed this study, 10 participants had device failure (device that did not perform well), and therefore 133 participants were included in PP population. | Posted | Number | Participants | 7 days |
|
|
|
| Primary | Which of the Following Statements Best Describes the Extent to Which the Spray Reached Your Expectations? | There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after at-home use of the product. Participants could select only one option. | The per protocol (PP) population was the primary population for analysis. Of the 143 participants who completed this study, 10 participants had device failure (device that did not perform well), and therefore 133 participants were included in PP population. | Posted | Number | Participants | 7 days |
|
|
|
| Primary | Divide 11 Points Between Two Products (CO2 Nasal Spray and Brand Selected at Q1)? | There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after at-home use of the product. Participants could select only one option. It was done to compare the spray with the product selected by the participant in Q1. There were 11 points between the two products that participants could divide anyways thet wanted (11-0, 10-1, 9-2, 8-3, 7-4 or 6-5 etc). The more the participant liked a product compared to other, the higher the number of points were to be given to that product. | The per protocol (PP) population was the primary population for analysis. Of the 143 participants who completed this study, 10 participants had device failure (device that did not perform well), and therefore 133 participants were included in PP population. | Posted | Number | Participants | 7 days |
|
|
|
| Primary | If the Product You Just Tried (After At-home Use) Was Available for the Following Price: $12.99 for 40 Doses, How Likely Would You be to Buy it? | There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after at-home use of the product. Participants could select only one option. | The per protocol (PP) population was the primary population for analysis. Of the 143 participants who completed this study, 10 participants had device failure (device that did not perform well), and therefore 133 participants were included in PP population. | Posted | Number | Participants | 7 days |
|
|
|
| Primary | How Many Packages Would You Buy? | There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience.This question was asked after at-home use of the product. Participants could select only one option. | The per protocol (PP) population was the primary population for analysis. Of the 143 participants who completed this study, 10 participants had device failure (device that did not perform well), and therefore 133 participants were included in PP population. | Posted | Number | Participants | 7 days |
|
|
|
| Primary | Which One Statement Best Describes How Often, if Ever, You Think You Would Buy the Spray Product in the Future? | There was one questionnaire used in this study which is divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after at-home use of the product. Participants could select only one option. | The per protocol (PP) population was the primary population for analysis. Of the 143 participants who completed this study, 10 participants had device failure (device that did not perform well), and therefore 133 participants were included in PP population. | Posted | Number | Participants | 7 days |
|
|
|
| Primary | How Often do You Think This Spray Product Would Last for You Personally? | There was one questionnaire used in this study which is divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after at-home use of the product. Participants could select only one option. | The per protocol (PP) population was the primary population for analysis. Of the 143 participants who completed this study, 10 participants had device failure (device that did not perform well), and therefore 133 participants were included in PP population. | Posted | Number | Participants | 7 days |
|
|
|
| Primary | Provide a Score From 1-7 to Some Statements, Depending on How Much You Think Each Statement Applies or Does Not Apply to the Spray Product That You Used | A score of 1 indicates that the statement does not apply at all to the product that you used. A score of 7 indicates that it applies completely to it. You can use any score from 1 to 7 to indicate how much or how little you think the statement applies to this product | The per protocol (PP) population was the primary population for analysis. Of the 143 participants who completed this study, 10 participants had device failure (device that did not perform well), and therefore 133 participants were included in PP population. | Posted | Number | Participants | 7 days |
|
|
|
| 0 |
| 147 |
| 75 |
| 147 |
| Throat irritation | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Epistaxis | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Rhinalgia | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Rhinorrhoea | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Cough | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Paraesthesia | Nervous system disorders | Systematic Assessment |
|
| Headache | Nervous system disorders | Systematic Assessment |
|
| Application site pain | General disorders | Systematic Assessment |
|
| Medical device site reaction | General disorders | Systematic Assessment |
|
| Lacrimation increased | Eye disorders | Systematic Assessment |
|
| Abdominal distension | Gastrointestinal disorders | Systematic Assessment |
|
GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
| D012120 |
| Respiration Disorders |
| D010038 | Otorhinolaryngologic Diseases |
| D017601 |
| Oxygen Compounds |
| Title | Measurements |
|---|---|
|
| Not as good as you expected |
|
| Not nearly as good as you expected |
|
| Title | Measurements |
|---|---|
|
| Probably would not buy |
|
| Definitely would not buy |
|
| Title | Measurements |
|---|---|
|
| Not quite as good |
|
| Not nearly as good |
|
| Title | Measurements |
|---|---|
|
| 3 for CO2 Nasal Spray |
|
| 4 for CO2 Nasal Spray |
|
| 5 for CO2 Nasal Spray |
|
| 6 for CO2 Nasal Spray |
|
| 7 for CO2 Nasal Spray |
|
| 8 for CO2 Nasal Spray |
|
| 9 for CO2 Nasal Spray |
|
| 10 for CO2 Nasal Spray |
|
| 11 for CO2 Nasal Spray |
|
| Title | Measurements |
|---|---|
|
| Probably would not buy |
|
| Definitely would not buy |
|
| Title | Measurements |
|---|
|
| 4 |
|
| 5 |
|
| Missing |
|
| Title | Measurements |
|---|---|
|
| Once every 3 weeks |
|
| Once a month |
|
| Once every 6 weeks |
|
| Once every 2 months |
|
| Once every 3 months |
|
| Once every 4-5 months |
|
| Title | Measurements |
|---|
|
| 1 Month |
|
| 6 Weeks |
|
| 2 Months |
|
| 3 Months |
|
| 4-5 Months |
|
| 6 Months |
|
| 9 Months |
|
| 1 Year |
|
| More than 1 year |
|
| Missing |
|
| Title | Measurements |
|---|---|
|
| Is easy to use; 4 |
|
| Is easy to use; 5 |
|
| Is easy to use; 6 |
|
| Is easy to use; 7 |
|
| Provides effective relief for nasal congestion; 1 |
|
| Provides effective relief for nasal congestion; 2 |
|
| Provides effective relief for nasal congestion; 3 |
|
| Provides effective relief for nasal congestion; 4 |
|
| Provides effective relief for nasal congestion; 5 |
|
| Provides effective relief for nasal congestion; 6 |
|
| Provides effective relief for nasal congestion; 7 |
|
| Provides instant relief; 1 |
|
| Provides instant relief; 2 |
|
| Provides instant relief; 3 |
|
| Provides instant relief; 4 |
|
| Provides instant relief; 5 |
|
| Provides instant relief; 6 |
|
| Provides instant relief; 7 |
|
| Provides long lasting relief; 1 |
|
| Provides long lasting relief; 2 |
|
| Provides long lasting relief; 3 |
|
| Provides long lasting relief; 4 |
|
| Provides long lasting relief; 5 |
|
| Provides long lasting relief; 6 |
|
| Provides long lasting relief; 7 |
|
| Helps you breathe better; 1 |
|
| Helps you breathe better; 2 |
|
| Helps you breathe better; 3 |
|
| Helps you breathe better; 4 |
|
| Helps you breathe better; 5 |
|
| Helps you breathe better; 6 |
|
| Helps you breathe better; 7 |
|
| Drug free; 1 |
|
| Drug free; 2 |
|
| Drug free; 3 |
|
| Drug free; 4 |
|
| Drug free; 5 |
|
| Drug free; 6 |
|
| Drug free; 7 |
|
| Is a product for someone like me; 1 |
|
| Is a product for someone like me; 2 |
|
| Is a product for someone like me; 3 |
|
| Is a product for someone like me; 4 |
|
| Is a product for someone like me; 5 |
|
| Is a product for someone like me; 6 |
|
| Is a product for someone like me; 7 |
|
| Prevents allergy symptoms; 1 |
|
| Prevents allergy symptoms; 2 |
|
| Prevents allergy symptoms; 3 |
|
| Prevents allergy symptoms; 4 |
|
| Prevents allergy symptoms; 5 |
|
| Prevents allergy symptoms; 6 |
|
| Prevents allergy symptoms; 7 |
|
| Effectively treats allergy symptoms; 1 |
|
| Effectively treats allergy symptoms; 2 |
|
| Effectively treats allergy symptoms; 3 |
|
| Effectively treats allergy symptoms; 4 |
|
| Effectively treats allergy symptoms; 5 |
|
| Effectively treats allergy symptoms; 6 |
|
| Effectively treats allergy symptoms; 7 |
|
| Is a brand I trust; 1 |
|
| Is a brand I trust; 2 |
|
| Is a brand I trust; 3 |
|
| Is a brand I trust; 4 |
|
| Is a brand I trust; 5 |
|
| Is a brand I trust; 6 |
|
| Is a brand I trust; 7 |
|
| Is a good value for the money; 1 |
|
| Is a good value for the money; 2 |
|
| Is a good value for the money; 3 |
|
| Is a good value for the money; 4 |
|
| Is a good value for the money; 5 |
|
| Is a good value for the money; 6 |
|
| Is a good value for the money; 7 |
|
| Is very effective; 1 |
|
| Is very effective; 2 |
|
| Is very effective; 3 |
|
| Is very effective; 4 |
|
| Is very effective; 5 |
|
| Is very effective; 6 |
|
| Is very effective; 7 |
|
| Is safe to use every day; 1 |
|
| Is safe to use every day; 2 |
|
| Is safe to use every day; 3 |
|
| Is safe to use every day; 4 |
|
| Is safe to use every day; 5 |
|
| Is safe to use every day; 6 |
|
| Is safe to use every day; 7 |
|
| Helps you sleep better; 1 |
|
| Helps you sleep better; 2 |
|
| Helps you sleep better; 3 |
|
| Helps you sleep better; 4 |
|
| Helps you sleep better; 5 |
|
| Helps you sleep better; 6 |
|
| Helps you sleep better; 7 |
|
| Effectively treats multiple symptoms; 1 |
|
| Effectively treats multiple symptoms; 2 |
|
| Effectively treats multiple symptoms; 3 |
|
| Effectively treats multiple symptoms; 4 |
|
| Effectively treats multiple symptoms; 5 |
|
| Effectively treats multiple symptoms; 6 |
|
| Effectively treats multiple symptoms; 7 |
|
| Does not cause side effects; 1 |
|
| Does not cause side effects; 2 |
|
| Does not cause side effects; 3 |
|
| Does not cause side effects; 4 |
|
| Does not cause side effects; 5 |
|
| Does not cause side effects; 6 |
|
| Does not cause side effects; 7 |
|
| Helps you feel better the next day; 1 |
|
| Helps you feel better the next day; 2 |
|
| Helps you feel better the next day; 3 |
|
| Helps you feel better the next day; 4 |
|
| Helps you feel better the next day; 5 |
|
| Helps you feel better the next day; 6 |
|
| Helps you feel better the next day; 7 |
|
| Helps you breathe more freely; 1 |
|
| Helps you breathe more freely; 2 |
|
| Helps you breathe more freely; 3 |
|
| Helps you breathe more freely; 4 |
|
| Helps you breathe more freely; 5 |
|
| Helps you breathe more freely; 6 |
|
| Helps you breathe more freely; 7 |
|
| Does not interact with any medications; 1 |
|
| Does not interact with any medications; 2 |
|
| Does not interact with any medications; 3 |
|
| Does not interact with any medications; 4 |
|
| Does not interact with any medications; 5 |
|
| Does not interact with any medications; 6 |
|
| Does not interact with any medications; 7 |
|
| Safe to use multiple times in a day; 1 |
|
| Safe to use multiple times in a day; 2 |
|
| Safe to use multiple times in a day; 3 |
|
| Safe to use multiple times in a day; 4 |
|
| Safe to use multiple times in a day; 5 |
|
| Safe to use multiple times in a day; 6 |
|
| Safe to use multiple times in a day; 7 |
|
| Prevents the release of histamine; 1 |
|
| Prevents the release of histamine; 2 |
|
| Prevents the release of histamine; 3 |
|
| Prevents the release of histamine; 4 |
|
| Prevents the release of histamine; 5 |
|
| Prevents the release of histamine; 6 |
|
| Prevents the release of histamine; 7 |
|
| Prevents nasal congestion before it starts; 1 |
|
| Prevents nasal congestion before it starts; 2 |
|
| Prevents nasal congestion before it starts; 3 |
|
| Prevents nasal congestion before it starts; 4 |
|
| Prevents nasal congestion before it starts; 5 |
|
| Prevents nasal congestion before it starts; 6 |
|
| Prevents nasal congestion before it starts; 7 |
|
| Stops nasal congestion where it starts; 1 |
|
| Stops nasal congestion where it starts; 2 |
|
| Stops nasal congestion where it starts; 3 |
|
| Stops nasal congestion where it starts; 4 |
|
| Stops nasal congestion where it starts; 5 |
|
| Stops nasal congestion where it starts; 6 |
|
| Stops nasal congestion where it starts; 7 |
|
| Can be used with other nasal congestion remedy; 1 |
|
| Can be used with other nasal congestion remedy; 2 |
|
| Can be used with other nasal congestion remedy; 3 |
|
| Can be used with other nasal congestion remedy; 4 |
|
| Can be used with other nasal congestion remedy; 5 |
|
| Can be used with other nasal congestion remedy; 6 |
|
| Can be used with other nasal congestion remedy; 7 |
|
| Can feel it working instantly; 1 |
|
| Can feel it working instantly; 2 |
|
| Can feel it working instantly; 3 |
|
| Can feel it working instantly; 4 |
|
| Can feel it working instantly; 5 |
|
| Can feel it working instantly; 6 |
|
| Can feel it working instantly; 7 |
|
| Works like no other product; 1 |
|
| Works like no other product; 2 |
|
| Works like no other product; 3 |
|
| Works like no other product; 4 |
|
| Works like no other product; 5 |
|
| Works like no other product; 6 |
|
| Works like no other product; 7 |
|
| Relieves my symptoms instantly; 1 |
|
| Relieves my symptoms instantly; 2 |
|
| Relieves my symptoms instantly; 3 |
|
| Relieves my symptoms instantly; 4 |
|
| Relieves my symptoms instantly; 5 |
|
| Relieves my symptoms instantly; 6 |
|
| Relieves my symptoms instantly; 7 |
|
| Improves my breathing instantly; 1 |
|
| Improves my breathing instantly; 2 |
|
| Improves my breathing instantly; 3 |
|
| Improves my breathing instantly; 4 |
|
| Improves my breathing instantly; 5 |
|
| Improves my breathing instantly; 6 |
|
| Improves my breathing instantly; 7 |
|
| Works as good as medicated nasal sprays; 1 |
|
| Works as good as medicated nasal sprays; 2 |
|
| Works as good as medicated nasal sprays; 3 |
|
| Works as good as medicated nasal sprays; 4 |
|
| Works as good as medicated nasal sprays; 5 |
|
| Works as good as medicated nasal sprays; 6 |
|
| Works as good as medicated nasal sprays; 7 |
|
| Works better than medicated nasal sprays; 1 |
|
| Works better than medicated nasal sprays; 2 |
|
| Works better than medicated nasal sprays; 3 |
|
| Works better than medicated nasal sprays; 4 |
|
| Works better than medicated nasal sprays; 5 |
|
| Works better than medicated nasal sprays; 6 |
|
| Works better than medicated nasal sprays; 7 |
|